Nicht aus der Schweiz? Besuchen Sie lehmanns.de

Lentivirus Gene Engineering Protocols

Maurizio Federico (Herausgeber)

Buch | Hardcover
228 Seiten
2009 | 2nd ed. 2010
Humana Press Inc. (Verlag)
978-1-60761-532-3 (ISBN)

Lese- und Medienproben

Lentivirus Gene Engineering Protocols -
CHF 194,70 inkl. MwSt
  • Versand in 10-15 Tagen
  • Versandkostenfrei
  • Auch auf Rechnung
  • Artikel merken
Authoritative and timely, Lentivirus Gene Engineering Protocols, Second Edition, covers the most relevant issues and techniques of LV-based gene engineering. This practical guide is aimed at those who wish to know more about this vital area of study.
Since the publication of the first edition, lentivirus vector-based technologies, through in vitro and in vivo gene transfer in eukaryotic animal cells, continue to offer the most promising opportunities for curing genetic disorders, as well as cancer and infectious diseases. Lentivirus Gene Engineering Protocols, Second Edition reflects the spectacular progress made in the field with a set of cutting-edge methods contributed by highly respected scientists. Beginning with a thorough overview of the most recent lentivirus developments, the book continues with detailed protocols including sections on the advances in lentiviral vector technology, new lentiviral vector applications, involving transgenic human embryonic stem cells and fetal gene therapy among other topics, as well as the invaluable breakthroughs in LV-mediated expression of microRNAs. Written in the highly successful Methods in Molecular Biology™ series format, chapters include introductions to their respective subjects, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and notes sections, highlighting tips on troubleshooting and avoiding known pitfalls.


Authoritative and timely, Lentivirus Gene Engineering Protocols, Second Edition covers the most relevant issues and techniques of LV-based gene engineering, thus representing a complete theoretical and practical guide for scientists still unfamiliar with LV technologies and those who simply wish to know more about this vital area of study.

Overview.- Lentiviral Vector-Mediated Gene Transfer and RNA Silencing Technology in Neuronal Dysfunctions.- Advances in Lentiviral Vector Technology.- New Protocol for Lentiviral Vector Mass Production.- Flexibility in Cell Targeting by Pseudotyping Lentiviral Vectors.- Doxycycline Regulated Lentiviral Vectors.- Strategies to Insulate Lentiviral Vector-Expressed Transgenes.- Integrase Defective, Nonintegrating Lentiviral Vectors.- Lentivirus-Based Virus-Like Particles as a New Protein Delivery Tool.- New Lentiviral Vector Applications.- Lentiviral Vector-Mediated Transgenesis in Human Embryonic Stem Cells.- Lentiviral Vector Transduction of Fetal Mesenchymal Stem Cells.- Manipulating the Cell Differentiation Through Lentiviral Vectors.- Lentiviral Vector Transduction of Dendritic Cells for Novel Vaccine Strategies.- The Short RNA Technologies Applied by Lentiviral Vectors.- Lentiviral Vector-Mediated Expression of pre-miRNAs and AntagomiRs.- The RNA Silencing Technology Applied by Lentiviral Vectors in Oncology.- Lentiviral Vector Engineering for Anti-HIV RNAi Gene Therapy.- Lentivirus-Expressed siRNA Vectors Against Alzheimer Disease.

Erscheint lt. Verlag 21.12.2009
Reihe/Serie Methods in Molecular Biology ; 614
Zusatzinfo XII, 228 p.
Verlagsort Totowa, NJ
Sprache englisch
Maße 178 x 254 mm
Themenwelt Naturwissenschaften Biologie Biochemie
Naturwissenschaften Biologie Genetik / Molekularbiologie
Naturwissenschaften Biologie Mikrobiologie / Immunologie
Naturwissenschaften Biologie Zellbiologie
Technik Umwelttechnik / Biotechnologie
ISBN-10 1-60761-532-0 / 1607615320
ISBN-13 978-1-60761-532-3 / 9781607615323
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich

von Reinhard Matissek; Andreas Hahn

Buch | Hardcover (2024)
Springer Spektrum (Verlag)
CHF 109,95

von Birgit Piechulla; Hans Walter Heldt

Buch | Hardcover (2023)
Springer Spektrum (Verlag)
CHF 109,95